Merck Collaborates with Google Cloud on AI Projects

• Merck will invest up to $1 billion over several years, with executives expecting at least a decade-long partnership focused on AI tools and Google Cloud engineers rather than just 'buying tokens'
• Merck has already used Google's AI technology to reduce the time and cost of compiling reimbursement dossiers by half and has been using AI to prepare clinical study report sections for roughly two years
• The partnership will deploy AI across the entire drug development process, including running computerized simulations of laboratory experiments and speeding regulatory processes, with dossiers already being submitted in markets using the new capability

Merck Partners with Google Cloud on AI Initiative Worth Up to $1 Billion

Key Deal Terms:

Merck & Co announced a strategic partnership with Google Cloud on April 22, committing up to $1 billion over several years to enhance its artificial intelligence capabilities. The investment will fund AI infrastructure, engineering resources, and licensing of Google's Gemini Enterprise platform, with executives expecting a decade-long collaboration.

Scope and Implementation:

The partnership, revealed at Google's Cloud Next conference in Las Vegas, will deploy AI across Merck's entire value chain, including drug research, regulatory affairs, manufacturing, and commercial operations. This builds on existing work between the companies, with Google Cloud engineers embedded directly with Merck teams.

Operational Impact:

Merck's Chief Information and Digital Officer Dave Williams emphasized this is not a pilot program but an active deployment. The company has already achieved significant results:

• 50% reduction in time and cost for compiling regulatory reimbursement dossiers
• Two years of successful AI use in preparing clinical study reports
• Current submission of AI-assisted dossiers in international markets with plans for global scaling

Strategic Rationale:

Both companies positioned the collaboration as accelerating drug development through AI-powered laboratory simulations and streamlined regulatory processes. Google Cloud CEO Thomas Kurian highlighted AI's societal benefit in healthcare, while Merck views this as addressing a "huge information challenge" in pharmaceutical development.

Market Context:

The deal represents a significant commitment by a major pharmaceutical company to cloud-based AI infrastructure, reflecting the industry's broader push toward digital transformation and computational drug discovery. Google Cloud is a unit of Alphabet Inc.